OpenAlex
PricingAboutJobs
Log inGet started
Work

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.

HTML

Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2012.30.15_suppl.5505
Authors: Joel Guigay, Jerome Fayette, Anne-Francoise Dillies, Christian Sire, Joseph N. Kerger, Isabelle Tennevet, Jean-Pascal H. Machiels, Sylvie Zanetta, Yoann Pointreau, Laurence Bozec Le Moal, Lydia Brugel Ribere, Stefanie Henry, Stéphane Temam, GORTEC
Institutions: Institut Gustave Roussy, Centre Léon Bérard, Centre Jean Perrin, Centre Hospitalier de Bretagne Sud, Centre Henri Becquerel, Cliniques Universitaires Saint-Luc, Centre Georges François Leclerc, Centre Hospitalier Universitaire de Tours, Hôpital Foch, Hôpital Intercommunal de Créteil
Language: English

Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Keywords: cetuximab, docetaxel, cisplatin, first-line chemotherapy, EGFR inhibition, objective response rate, progression-free survival, overall survival, lenograstim, G-CSF support, maintenance therapy, biomarkers
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2296828792
Cites:
Cited by: 41
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security